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Methamphetamine and MDMA have been called safe drugs of abuse. Worldwide there is an increased consumption of these drugs, which has become a focus of
research in South Africa. As the number of methamphetamine users has increased in many African countries, it is essential that emergency care practitioners are able
to diagnose and manage intoxication with methamphetamine, MDMA, and other derivatives. The most common presentations include restlessness, agitation, hyper-
tension, tachycardia, and headache while hyperthermia, hyponatraemia, and rhabdomyolysis are among the most common serious complications. Most deaths are sec-
ondary to hyperthermia complicated by multiple organ failure. A number of laboratory analyses should be obtained if locally available. We provide a review of the
current recommended general and speciﬁc management approaches. Benzodiazepines are the ﬁrst line therapy for hyperthermia, agitation, critical hypertension, and
seizures. Patients with serious complications are best managed in an intensive care unit if available. Emergency centres should create protocols and/or further train staff
in the recognition and management of intoxication with these ‘not so safe’ drugs.La me´thamphe´tamine et le MDMA ont e´te´ qualiﬁe´es de drogues « re´cre´atives ». Partout dans le monde, la consommation de ces drogues est en augmentation, ce qui a
attire´ l’attention des chercheurs en Afrique du Sud. Du fait que le nombre d’usagers de me´thamphe´tamine a augmente´ dans plusieurs pays d’Afrique, il est primordial
que les me´decins des services d’urgence soient capables de diagnostiquer et de prendre en charge une intoxication a` la me´tamphe´tamine, au MDMA et autres de´rive´s.
Les symptoˆmes les plus fre´quents sont la nervosite´, l’agitation, l’hypertension, la tachycardie et les maux de teˆte, l’hyperthermie, l’hyponatre´mie et la rhabdomyolise
e´tant les complications se´rieuses les plus fre´quentes. La plupart des de´ce`s font suite a` une hyperthermie qui se complique par une de´faillance multivisce´rale. Il
conviendra de proce´der a` des analyses de laboratoire, si elles sont localement disponibles. Nous fournissons un compte-rendu des modes de prise en charge ge´ne´raux
et spe´ciﬁques actuellement pre´conise´s. Les benzodiaze´pines constituent le traitement de premie`re intention pour l’hyperthermie, l’agitation, l’hypertension se´ve`re et les
crises. Les patients pre´sentant des se´rieuses complications devraient eˆtre pris en charge dans une unite´ de soins intensifs, le cas e´che´ant. Les services d’urgence devraient
de´velopper des protocoles et/ou former leur personnel a` la reconnaissance et la prise en charge de l’intoxication par ces drogues qui ne sont pas aussi « re´cre´atives »
qu’elles le paraissent.African relevance
 The prevalence of methamphetamine use is increasing in
Africa.
 Patients with methamphetamine or MDMA intoxication
often present to an emergency centre and thus emergency
health practitioners should be comfortable with appropriate
management.
 The use of methamphetamine often leads to increased sex-
ual risk taking behaviour, which could fuel the spread of
HIV infection. This is of particular concern in areas with
high HIV prevalence.Introduction
Methamphetamine, popularly known as ‘tik’ in South Africa
and ‘speed’ or ‘crystal meth’ in the United States, is a sympat-
homimetic amine that has stimulant, anorexiant, euphoric, and
hallucinogenic effects. It was ﬁrst synthesized in 1893 and is
clinically used for the treatment of attention deﬁcit disorder
with hyperactivity, short-term treatment of obesity, and as
an off-label treatment for narcolepsy. It is the most widely
abused drug worldwide after cannabis and can be synthesized
using readily available chemicals and adrenaline or
pseudoadrenaline.1
MDMA (3,4-methylenedioxymethamphetamine), popu-
larly known as ‘ecstasy’ in the United States, is a synthetic
compound with pharmacologic similarities to amphetamines.
It was ﬁrst introduced by Merck in 1914 as an appetite sup-
pressant for animals and later used in psychotherapy.2 Since
the late 1970s, it is primarily used as a recreational street drug
to produce euphoric effects, in particular at urban dance
parties.
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amine and its derivative MDMA, relatively few people experi-
ence serious adverse events.3,4 Emergency practitioners must
be able to both recognize that these drugs have a signiﬁcant
risk of physical harm and psychological disturbances and to
assess and manage intoxication.5–8
Epidemiology
The use of amphetamines has reached epidemic proportions
around the world.9 In Africa, methamphetamine has become
a major drug of abuse.10 The United Nations estimates that
280,000–780,000 South Africans used amphetamines in
2011.1 The South African Medical Research Council estimates
that 7% of the population in Cape Town is using methamphet-
amine.11 There has been an increase in both drug treatment
and psychiatric admissions related to the use of methamphet-
amine in South Africa, especially in adolescent
populations.12,13
Lifetime use of MDMA in Canada for those older than
15 years was 3% and 5.2% for women and men, respectively,
and in the United States was reported at 5.8% in grade 9–12
students.14,15 Australian surveys report up to 20% of those
aged 20–29 years have used MDMA.16 The United Nations
estimates that 190,000–300,000 South Africans used MDMA
in 2011. Estimates are not available for other parts of Africa.1
Pharmacology
Methamphetamine acts as an indirect neurotransmitter by dis-
placing adrenaline, noradrenaline, dopamine, and serotonin
into the cytosol, which then diffuse into the synapse activating
postsynaptic receptors. Reuptake systems are also disturbed.
The release of adrenaline and noradrenaline activates alpha
and beta receptors causing hypertension, tachycardia, hyper-
thermia, and vasospasm. Serotonin release leads to mood
changes and alterations in hunger and thirst responses. The
observed drug-craving and drug-seeking behaviour and psychi-
atric symptoms can be attributed to the excessive dopamine
receptor stimulation. The half-life is 12–34 h but the duration
of effect may persist beyond 24 h.17
MDMA differs from traditional amphetamines in that it is
structurally similar to serotonin and therefore carries a higher
risk of serotonin syndrome. It is typically ingested in a tablet
form and dosages in the illicit forms vary widely.
Clinical evaluation
Patient presentations are varied due to the wide range of phys-
ical, psychological, and physiological effects of amphetamines.
Methamphetamine or MDMA intoxication should be consid-
ered in any patient with diaphoresis, severe agitation, psycho-
sis, tachycardia, and hypertension. As in all emergent
situations, airway, breathing, and circulation should be consid-
ered initial priorities prior to obtaining a clinical history.
Medical history
If the patient can provide a history, the emergency centre
health professional should determine the route of exposureand frequency of use. The patient should be asked about the
amphetamine identity, quantity consumed, and time of expo-
sure. The location of exposure is also important as those in
crowded clubs are at increased risk of metabolic disturbances
and hyperthermia.18 Patients who complain of chest pain, pal-
pitations, headache, visual disturbance, or other focal neuro-
logical symptoms will require immediate assessment. A
history of co-ingestants should be obtained as other stimulant
drugs, monoamine oxidase inhibitors, and tricyclic antidepres-
sants are synergistic. Certain prescribed medications, such as
ritonavir, reduce hepatic metabolism of amphetamines and
thus prolong their toxicity.19 Personal medical history is
important as those with underlying cardiorespiratory disease
or seizure disorders will likely be less tolerant of amphetamine
toxicity.
Physical examination
After initial assessment of airway, breathing, and circulation,
patients should be assessed for signs of life-threatening distur-
bances. Clinical signs indicating signiﬁcant amphetamine tox-
icity include seizure, focal neurological deﬁcits, reduced level
of consciousness, abnormal motor movements, hyperthermia,
dysrhythmias, hypotension, hypertension, acute coronary syn-
drome, and autonomic instability.20 Prognostic factors for
mortality include shock, coma, temperature >39 oC, acute re-
nal failure, metabolic acidosis, and hyperkalaemia (K> 5.6).21
Virtually all intoxicated patients will have tachycardia and
hypertension.
The most common manifestations in patients with MDMA
intoxication include restlessness, agitation, confusion, hyper-
tension, and headache. The other common manifestations of
MDMA intoxication are similar to those seen in methamphet-
amine intoxication (see Table 1). The most common serious
complications are hyperthermia, Hyponatraemia, and rhabdo-
myolysis (see Table 2).22 Acute coronary syndrome is a poten-
tial complication and presentation may be delayed.23,24
Hyponatraemia may be due to drug-mediated anti-diuretic
hormone release or marked increase in ﬂuid intake, the latter
of which is seen in some MDMA users due to the belief that
drinking large amounts of water will avoid hyperthermia.25,26
Patients using MDMA are at increased risk of serotonin
syndrome, which presents as the triad of autonomic dysfunc-
tion, abnormal neuromuscular activity, and altered mental
status.
Deaths due to methamphetamine or MDMA intoxication
occur in young, healthy people and are likely under-
reported.27,28 Most deaths are secondary to hyperthermia
complicated by multi-organ failure (severe dehydration, renal
failure, liver failure, and/or disseminated intravascular
coagulation).29,30Differential diagnosis
There are both toxicologic and non-toxicologic conditions that
mimic methamphetamine and MDMA intoxication (see
Table 3). In order to distinguish from methamphetamine
intoxication, particular attention should be paid to duration
of action and clinical signs speciﬁc to intoxication with other
substances.31
Table 1 Common manifestations of MDMA intoxication.
Aggression Agitation Anger
Anxiety Confusion Dehydration
Depression Diaphoresis Dilated pupils
Disorientation Dulling of senses Fainting
Hallucinations Headache Hypertension
Lack of judgment Loss of consciousness Mood changes
Nausea Paranoia Psychosis
Restlessness Sleep disturbance Speech disturbance
Tachycardia Teeth grinding Tremulousness
Table 2 Serious complications with methamphetamine or
MDMA intoxication.
Cardiac arrhythmia Cerebral oedema Coma
Death DIC Hyperthermia
Hyponatraemia Intracranial haemorrhage Liver failure
Metabolic acidosis Myoglobinuric renal failure Pneumonia
Respiratory arrest Rhabdomyolysis Seizure
Serotonin syndromea Stroke Trauma
a More common in MDMA intoxication.
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When available, routine testing should include ﬁngerstick glu-
cose, paracetamol and salicylate levels, electrocardiogram, and
pregnancy test in women of childbearing age. A urine drug
screen is of limited value as not all sympathomimetic drugs
are identiﬁed and the test will be positive for days after use.
Serum and urine assays for MDMA are not useful. When sig-
niﬁcant toxicity is suspected, serum laboratory tests are recom-
mended. Additional studies may be indicated based on the
clinical presentation (See Table 4).20
Management
Aggressive supportive care is essential. Close attention to and
correction of hypotension, hyperthermia, hypoxia, and acid–
base and metabolic abnormalities will signiﬁcantly reduce
morbidity and mortality. As such, vital signs need to be ob-
tained in a timely fashion and patients should be kept on con-
tinuous cardiovascular monitoring if available.
General management of any intoxication includes attention
to decontamination and elimination. In the case of ampheta-
mines, activated charcoal for decontamination plays a very
limited role. It can potentially decrease absorption if adminis-
tered within one hour of ingestion but the majority of patients
present outside this timeframe.32 As amphetamines are weak
bases, urine acidiﬁcation could potentially enhance amphet-
amine elimination. Despite this, it is contraindicated as urine
acidiﬁcation can potentiate adverse effects of rhabdomyolysis
and worsen metabolic acidosis.33
Emergent consultations with a medical toxicologist are rec-
ommended if considering gastrointestinal decontamination in
the case of recent large ingestion. Such consultations are avail-
able by telephone in certain locations worldwide. The World
Health Organization lists all international poison centres. As
of February 2012, African poison control centres exist in Alge-
ria, Ghana, Kenya, Morocco, Senegal, South Africa, Tunisia,
and Zimbabwe (see Appendix B).34
Hyperthermia has been associated with amphetamine re-
lated deaths and thus it should be treated promptly. Aggressive
cooling with core body temperature monitoring should be
initiated for hyperthermia since it is the most important deter-
minant of mortality. Hyperthermia speciﬁcally due to MDMA
intoxication will often be associated with other clinical signs of
serotonin syndrome.35,36 External cooling methods can be used
to lower body temperature and intravenous crystalloids should
be administered for dehydration. Administering benzodiaze-
pines will control agitation and decrease muscle activity that
leads to hyperthermia. Lorazepam dosed at 1–4 mg or diaze-
pam 5–10 mg may be used and repeated every 8–10 min. If
there is no IV access, midazolam 5–10 mg can be injected intra-
muscularly and this can be repeated every 10 min. If paralysis
and tracheal intubation are necessary, succinylcholine should
not be used for rapid sequence intubation due to the risk of
rhabdomyolysis.
The use of dantrolene in the setting of MDMA induced
hyperthermia has been controversial. A systematic review from
2010 of cases dating back to 2008 found the proportion of sur-
vivors to be higher in the dantrolene treated patients, especially
in cases of extreme (>42 oC) and severe (>40 oC) fever. No
adverse events were reported with the use of dantrolene exceptfor a potential association with transient hypoglycaemia.37 De-
spite this, it is unclear if the decreased mortality is due to dan-
trolene alone or a combination of interventions.38 In instances
of amphetamine-related refractory hyperthermia, serotonin
toxicity should be considered. Cyproheptadine is a 5HT2a
antagonist and has been used successfully in case reports.39,40
One animal study explored the use of carvedilol in treating
MDMA-induced hyperpyrexia.41 A recent human study in
healthy subjects suggests a potential role for carvedilol in
reducing hyperthermia, hypertension and tachycardia caused
by MDMA toxicity.42 These are currently not standard
treatments.
Agitation should be treated aggressively with patients cared
for in a quiet environment. Physical restraints should not be
used unless chemical restraint is not available as the muscle
contractions associated with resisting restraints have been
associated with lactic acidosis, hyperthermia, sudden cardiac
collapse, and death. Benzodiazepines are considered ﬁrst line
pharmacologic management of agitation. The use of antipsy-
chotics such as haloperidol or droperidol is controversial as
they can interfere with heat dissipation, prolong QT interval,
and reduce the seizure threshold.43
Seizures can be amphetamine-induced, secondary to hyp-
onatraemia, or related to intracerebral pathology such as
haemorrhage, ischaemia, or infarction. Most are amphet-
amine-induced and should be treated with benzodiazepines
with the use of phenobarbitone as a second-line agent. If unre-
sponsive to these interventions, general anaesthetic sedation
using thiopentone, propofol, or midazolam can be used. Any
patient with suspected intracranial pathology should have
head imaging if available.20
Critical hypertension is managed with benzodiazepines. If
additional blood pressure agents are needed, then nitroglyc-
erin, nitroprusside, and phentolamine may be used. Pure
beta-blocking agents should be avoided due to the risk of
unopposed alpha-receptor stimulation and subsequent
Table 3 Differential diagnosis.
Toxicologic Nontoxicologic
Cocaine Heat stroke
Phencyclidine (PCP) Thyrotoxicosis
Theophylline/caﬀeine Pheochromocytoma
Aspirin Sepsis/meningitis/encephalitis
Monoamine oxidase inhibitors Hypoglycaemia/hyperglycaemia
Serotonin syndrome Intracerebral haemorrhage
Anticholinergic poisoning
Table 4 Laboratory testing and other studies.
Fingerstick glucose If reduced consciousness
Electrolytes, renal function Exclude Hyponatraemia and
hyperkalaemia
Creatinine kinase Look for rhabdomyolysis
Coagulation screen Exclude disseminated
intravascular coagulation
Liver function tests Look for hepatitis
Arterial blood gas analysis To detect metabolic
disturbances
Serial cardiac enzymes Assess possible acute coronary
syndrome (ACS)
Electrocardiogram Assess for ACS/dysrhythmias
Chest radiograph To rule out aortic dissection or
pneumothorax
Abdominal radiograph If suspicion of ingested packets
of amphetamine
CT brain If concern for stroke, cerebral
oedema, trauma
Echocardiography If concern for cardiomyopathy
Adapted from Greene et al.20
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sial.44,45 One study of cocaine users showed that it attenuated
cocaine-induced increases in heart rate and blood pressure.46
Hyponatraemia can be a signiﬁcant serious complication
of amphetamine intoxication and should be excluded early,
especially in patients with altered mental status or seizures.
In one study, 38.8% of patients with MDMA ingestion pre-
sented with hyponatremia.47 Mild to moderate hyponatra-
emia in a non-dehydrated patient can be treated with ﬂuid
restriction. Normal saline should be used if intravenous ﬂu-
ids are required. Severe hyponatraemia with seizures is trea-
ted cautiously with benzodiazepines and hypertonic saline
with a goal of cessation of seizures. X mL/kg of 3% saline
will raise the sodium by X mmol/L.20 Mannitol has been
used for symptomatic hyponatraemia secondary to MDMA
ingestion but data are currently restricted to case
reports.48,49 The use of mannitol is not a currently standard
treatment.
Rhabdomyolysis may result from increased muscle motor
activity and can lead to severe hyperkalemia.50 Fluid resusci-
tation should aim for a urine output goal of 1–2 cc/kg/hr
to prevent myoglobinuric renal failure. Patients with concom-
itant myocardial dysfunction with a risk of pulmonary
oedema or symptomatic hyponatraemia will need close ﬂuid
management monitoring due to competing goals.51 Urinary
alkalinization is not recommended as it inhibits amphetamineelimination. The use of bicarbonate to alkalinize the urine
and the use of mannitol have not proven to improve
end-point measures of morbidity, mortality, or the need for
dialysis.52
Most patients can be safely discharged after a period of
observation – up to 6 h or once asymptomatic. Some patients
may require admission for vital signs monitoring, intravenous
ﬂuids, and administration of benzodiazepines. Those with seri-
ous complications may need to be managed in the intensive
care unit for a prolonged period.22 All patients should be edu-
cated about the dangers of amphetamine use.
Conclusion
Although the popular image of methamphetamine and
MDMA is that of ‘safe’ drugs, clinical practice and data show
otherwise. Knowledge of the clinical manifestations and imme-
diate management of methamphetamine and MDMA intoxi-
cation is essential for emergency medicine practitioners
worldwide, especially in Africa where use of these drugs has
boomed in the past decade. Most intoxications do not require
long-term admission, but acute and chronic use of these drugs
presents the risk of serious complications including death.
When patients present to emergency centres with symptoms
of agitation and vital sign alterations, methamphetamine or
MDMA use must be in the differential diagnosis. Amphet-
amine use is of particular concern as more adolescents are
now using these drugs. Furthermore, some researchers are con-
cerned that the use of methamphetamine leading to increased
sexual risk-taking behaviour could fuel the spread of HIV
infection.10,11,53,54 Emergency centres in Africa should update
or create protocols regarding the immediate assessment and
management of amphetamine intoxication in order to provide
efﬁcient, standardized care that reduces associated morbidity
and mortality.
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